Evidence map›Paper›PMID 30962424›Full record

Trial reportBlood cancer journal2019

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Katja C Weisel, Christof Scheid, Manola Zago, Britta Besemer, Elias K Mai, Mathias Haenel, Jan Duerig, Markus Munder, Hans-Walter Lindemann, Anja Seckinger and 6 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.Journal of cancer research and clinical oncology · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Katja C WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.weisel@uke.de.
Christof ScheidDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
Manola ZagoCenter for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany.
Britta BesemerDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
Elias K MaiDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6226-1252
Mathias HaenelClinic of Internal Medicine III, Hematology and Oncology, Clinic of Chemnitz, Chemnitz, Germany.
Jan DuerigDepartment of Hematology, University Hospital Essen, Essen, Germany.
Markus MunderDepartment of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz, Germany.
Hans-Walter LindemannClinic for Haematology/Oncology, Catholic Hospital Hagen, Hagen, Germany.
Anja SeckingerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Christina KunzDivision of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7238-6956
Dirk HoseDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Hans SalwenderDepartment of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneFemaleHumansMaleMultiple MyelomaProgression-Free SurvivalThalidomideCyclophosphamideDexamethasonepomalidomideThalidomide

Identifiers

PMID30962424
PMCPMC6453945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.